Updates & Press Releases

  • Healis Therapeutics' asset CKDB-501A published efficacy and safety data for glabellar injections from South Korea study

    Phase III results from South Korea bring Healis one step closer to delivering a novel BoNT/A developed for neuropsychiatry to the United States and Europe

    Read More

  • Healis Therapeutics Announces Partnership with CKD Bio

    Healis announced it has entered into a supply agreement to develop CKDB-501 for neuropsychiatric indications

    Read More

  • Healis selected to present at key biotech investor conferences in Amsterdam, New York, and San Diego

    BIO-Neuroscience Amsterdam
    BIO CEO Investor Conference NYC
    BIOCOM San Diego

    Read More

  • Healis selected to speak on opening day of 2024 Biotech Showcase in San Francisco

    Healis Co-Founders Sebastian De Beurs and Dr. Eric Finzi will be presenting on the company's neurotherapeutics pipeline and clinical development.

    Read More

  • BIO 2023: Healis Therapeutics publishes research on lead protein: BoNT/A for psychiatry

    Healis shares publication by Dr. Eric Finzi in journal Toxins, presenting a groundbreaking approach to treating depression.

    Read More

  • Healis Therapeutics acquires ownership of key botulinum toxin patent

    IP to accelerate the development of botulinum toxin as a candidate for treating major depressive disorder (MDD)

    Read More